324 results on '"Kodani, Eitaro"'
Search Results
2. Is atrial fibrillation a suitable target for studies on blood pressure variability?
3. Characteristics and outcomes in elderly patients with non-valvular atrial fibrillation and high bleeding risk: subanalysis of the J-RHYTHM Registry
4. Impact of heart rate on adverse events in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
5. Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
6. PREDICTIVE VALUE OF VARIOUS BLOOD PRESSURE INDICES FOR ADVERSE EVENTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE J-RHYTHM REGISTRY
7. SECOND DERIVATIVE OF THE FINGER PHOTOPLETHYSMOGRAPHY PREDICTS THE RISK OF FUTURE DEVELOPMENT OF HYPERTENSION IN MIDDLE-AGED MALE POPULATION
8. Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
9. Abstract 12308: Presenilin-2 Regulates Mitophagy via Promoting Intracellular Translocation of Parkin to Mitochondria
10. Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
11. New-onset atrial fibrillation before or after myocardial Infarction, which is worse for mortality?
12. A Novel Bleeding Risk Stratification Scheme in Japanese Patients with Non-valvular Atrial Fibrillation: The J-RISK AF study
13. Predictive ability of visit-to-visit blood pressure indices for adverse events in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry
14. Cholesterol levels of Japanese dyslipidaemic patients with various comorbidities: BioBank Japan
15. Survival of macrovascular disease, chronic kidney disease, chronic respiratory disease, cancer and smoking in patients with type 2 diabetes: BioBank Japan cohort
16. Abstract 13625: Effect of Empagliflozin versus Placebo on Plasma Volume Status in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the Embody Trial
17. Abstract 13363: Renoprotective Effects of Empagliflozin in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus; Subgroup Analysis of the Embody Trial
18. Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
19. Impact of Body Mass Index on the Prognosis of Japanese Patients With Non-Valvular Atrial Fibrillation
20. Net clinical benefit of adding aspirin to warfarin in patients with atrial fibrillation: Insights from the J-RHYTHM Registry
21. Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry
22. Factors Influencing Sarcopenic Changes in YUBI-WAKKA Finger-Ring Test Results After One Year: A Retrospective Observational Study
23. External Validation of the Kumamoto Criteria in Transthyretin Amyloid Cardiomyopathy Screening ― A Retrospective Cohort Study ―
24. Sarcopenia and coexistent risk factors detected using the ‘Yubi-wakka’ (finger-ring) test in adults aged over 65 years in the public annual health check-up in Tama City, Tokyo: a cross-sectional study
25. Direct Oral Anticoagulants Are Now Available for Patients With Atrial Fibrillation and Bioprosthetic Heart Valves
26. Impact of Systolic Blood Pressure Time in Target Range on Adverse Events in Patients With Nonvalvular Atrial Fibrillation (from the J-RHYTHM Registry)
27. Surgical Treatment of a Giant Popliteal Venous Aneurysm and Arteriovenous Fistula on the Adjacent Femoral Vein and Its Postoperative Findings
28. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry
29. Development of a risk prediction model for incident hypertension in a working-age Japanese male population
30. A case of acute myocardial infarction due to coronary artery compression by mediastinal hematoma associated with thoracic aortic aneurysm rupture
31. Impact of Heart Rate on Adverse Events in Patients with Non-Valvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry
32. Clinical phenotypes of patients with non-valvular atrial fibrillation as defined by a cluster analysis: A report from the J-RHYTHM registry
33. Relation of Smoking Status to Serum Levels of N-Terminal Pro–Brain Natriuretic Peptide in Middle-Aged Men Without Overt Cardiovascular Disease
34. Myocardial ultrastructure can augment genetic testing for sporadic dilated cardiomyopathy with initial heart failure
35. Utility of rapid D-dimer measurement for screening of acute cardiovascular disease in the emergency setting
36. Impact of baseline blood pressure on adverse outcomes in Japanese patients with non-valvular atrial fibrillation: the J-RISK AF.
37. Comparison among random forest, logistic regression, and existing clinical risk scores for predicting outcomes in patients with atrial fibrillation: A report from the J‐RHYTHM registry
38. Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus
39. Direct comparison between pharmacological stress with adenosine triphosphate disodium and exercise stress myocardial perfusion imagings
40. Coronary artery revascularization before peripheral vascular surgery in patients with peripheral arterial disease
41. JCS/JHRS2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
42. Should We Use Paclitaxel-Containing Devices for Endovascular Treatment of Peripheral Artery Disease?
43. Additional file 2 of Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
44. Additional file 4 of Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
45. Additional file 3 of Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
46. Additional file 1 of Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
47. Status of Medical Care and Management Requirements of Elderly Patients With Heart Failure in a Comprehensive Community Health System ― Survey of General Practitioners’ Views ―
48. Anemia and atrial fibrillation as independent risk factors for new-onset chronic kidney disease: the TAMA-MED Project—CKD and AF
49. Atrial fibrillation and stroke prevention: state of the art—epidemiology and pathophysiology: new risk factors, concepts and controversies
50. Protein tyrosine kinase signaling is necessary for NO donor-induced late preconditioning against myocardial stunning
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.